(HealthDay News) — For patients in the Apixaban for Reduction of Stroke and Other Thromboembolic Complications in Atrial Fibrillation (ARISTOTLE) trial, the 5 mg twice daily dose of apixaban is ...
Among patients hospitalized for atrial fibrillation (AF) or flutter, prescription of an off-label dose of a direct oral anticoagulant (DOAC) at discharge remains relatively common, according to data ...
Apixaban may be safer and more effective than rivaroxaban for treating nonvalvular atrial fibrillation (AF), a new observational study suggests. The study, one of the largest to compare the two drugs ...
Very elderly people with nonvalvular atrial fibrillation (Afib) got the same stroke prevention benefits from edoxaban (Savaysa) and apixaban (Eliquis), though one drug was associated with more major ...
Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Older adults ...
The efficacy and safety of apixaban for VTE prophylaxis in major orthopedic surgery have been evaluated in one Phase II trial and three Phase III trials. Traditional treatment of acute VTE entails ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results